Treatment of relapsed canine lymphoma with doxorubicin and dacarbazine

J Vet Intern Med. Jul-Aug 1990;4(4):187-91. doi: 10.1111/j.1939-1676.1990.tb00896.x.

Abstract

Fifteen dogs with relapsed lymphoma were treated with doxorubicin and dacarbazine (ADIC) to reinduce remission. All the dogs' lymphomas had become resistant to prior therapy with doxorubicin alone. Five of the 15 dogs had a complete response to the first treatment with ADIC, and three had partial responses. Of the eight dogs receiving a second cycle, two had complete responses, and one had a partial response. One dog that received a third ADIC treatment no longer responded. The median survival time from the first ADIC treatment for all dogs was 45 days (range, 18-241 days). The five dogs having complete responses to the first ADIC treatment had a median survival time of 105 days (range, 45-241 days) after this treatment. Toxicity due to ADIC treatment was acceptable and did not exceed that seen when doxorubicin was given as a single agent. The treatment resulted in severe neutropenia in three dogs. One dog died due to neutropenic sepsis. Vomiting, diarrhea, and anorexia occurred, but were tolerable, resulting in hospitalization in only one instance. ADIC is apparently a useful chemotherapeutic combination to reinduce remission in some dogs with relapsed lymphoma.

MeSH terms

  • Animals
  • Antineoplastic Combined Chemotherapy Protocols / adverse effects
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Dacarbazine / administration & dosage
  • Dacarbazine / adverse effects
  • Dog Diseases / chemically induced
  • Dog Diseases / drug therapy*
  • Dog Diseases / pathology
  • Dogs
  • Doxorubicin / administration & dosage
  • Doxorubicin / adverse effects
  • Female
  • Lymphoma / drug therapy
  • Lymphoma / pathology
  • Lymphoma / veterinary*
  • Male
  • Neoplasm Recurrence, Local / drug therapy
  • Neoplasm Recurrence, Local / veterinary*
  • Neutropenia / chemically induced
  • Neutropenia / veterinary
  • Retrospective Studies

Substances

  • Dacarbazine
  • Doxorubicin